Eton Pharma rises after upbeat Q2 results

Eton Pharmaceuticals

11/08/2023 10:57

** Shares of drug developer Eton Pharmaceuticals  ETON.O 
rise 31.5% to $3.42 premarket 
    ** ETON late on Thursday reported Q2 profit vs year ago
loss, driven by robust demand for its cortisol hormone
replacement therapy and hyperammonemia treatment
    ** Hyperammonemia is a rare genetic disorder which causes
elevated blood levels of ammonia
    ** Co reported Q2 adj. profit of $0.15/shr, vs year ago loss
of $0.06/shr
    ** Analysts were expecting a loss of $0.09/shr -Refinitiv
    ** Co posted total revenues of $12 mln vs analysts'
estimates of $6.5 mln -Refinitiv
    ** Up to last close, stock down 7.8% YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))